SRSF8

Across TCGA pan-cancer cohorts, SRSF8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRSF8 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SRSF8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SRSF8 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where SRSF8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.783	0.603	.012	17	view →
PDAC	DFS	Median	III,IV	0.530	0.186	.012	12	view →
CCRCC	OS	Median	III,IV	0.985	0.133	.027	5	view →
LUAD	OS	Tertile	All	0.603	0.891	.023	4	view →
HNSC	DFS	Tertile	III,IV	0.324	0.790	.049	4	view →
LSCC	OS	Quartile	II,III,IV	0.880	0.487	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRSF8–GBM (DFS)

Open the GBM breakdown →